BridgeBio Pharma Employee Directory

BridgeBio Pharma corporate office is located in 3160 Porter Dr Ste 250, Palo Alto, California, 94304, United States and has 1K - 5K employees.

Likely to Engage tag.Highly Engaged Employees

Employees by Department

Departments

Number of employees

Sales

99

Medical & Health

75

Operations

69

Engineering & Technical

60

Marketing

28

Legal

22

Finance

22

Key Employees of BridgeBio Pharma

BridgeBio Pharma Global Presence

globalPresence illustration
North America501-1,000
Europe11-50
Asia1-10
South America1-10

Index of contact profiles from BridgeBio Pharma

Hundreds of professionals searching for BridgeBio Pharma have connected with key decision-makers. Join them?
Contact Name
Contact Info
Job Title
HQ Location
12345

Former Employees at BridgeBio Pharma

Explore people who held key positions, contributed to BridgeBio Pharma's success, and advanced their careers.

People from Similar Companies in the Manufacturing Industry Located in California, United States

Frequently Asked Questions Regarding BridgeBio Pharma Employees

How many employees does BridgeBio Pharma have?
BridgeBio Pharma has 1K - 5K employees
Who is the CFO of BridgeBio Pharma?
BridgeBio Pharma’s CFO is Thomas Trimarchi
Who are BridgeBio Pharma key employees?
Some of BridgeBio Pharma key employees are Thomas Trimarchi, Riccardo Panicucci
Where is BridgeBio Pharma located?
BridgeBio Pharma’s headquarters are located at 3160 Porter Dr Ste 250, Palo Alto, California, 94304, United States
How do I contact BridgeBio Pharma?
BridgeBio Pharma Contact Info: Phone number: (650) 391-9740 Website: www.bridgebio.com
What does BridgeBio Pharma do?

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial... for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631.Read More

Is BridgeBio Pharma a public company?
Yes, BridgeBio Pharma is a public company and is traded under the symbol BBIO
See more information about BridgeBio Pharma Employees

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.